The Experts below are selected from a list of 360 Experts worldwide ranked by ideXlab platform
Artem V. Gelis - One of the best experts on this subject based on the ideXlab platform.
-
aqueous complexation of thorium iv uranium iv neptunium iv plutonium iii iv and cerium iii iv with DTPA
Inorganic Chemistry, 2012Co-Authors: Alex M. Brown, Alena Paulenova, Artem V. GelisAbstract:Aqueous complexation of Th(IV), U(IV), Np(IV), Pu(III/IV), and Ce(III/IV) with DTPA was studied by potentiometry, absorption spectrophotometry, and cyclic voltammetry at 1 M ionic strength and 25 °C. The stability constants for the 1:1 complex of each trivalent and tetravalent metal were calculated. From the potentiometric data, we report stability constant values for Ce(III)DTPA, Ce(III)HDTPA, and Th(IV)DTPA of log β101 = 20.01 ± 0.02, log β111 = 22.0 ± 0.2, and log β101 = 29.6 ± 1, respectively. From the absorption spectrophotometry data, we report stability constant values for U(IV)DTPA, Np(IV)DTPA, and Pu(IV)DTPA of log β101 = 31.8 ± 0.1, 32.3 ± 0.1, and 33.67 ± 0.02, respectively. From the cyclic voltammetry data, we report stability constant values for Ce(IV) and Pu(III) of log β101 = 34.04 ± 0.04 and 20.58 ± 0.04, respectively. The values obtained in this work are compared and discussed with respect to the ionic radius of each cationic metal.
-
Aqueous Complexation of Thorium(IV), Uranium(IV), Neptunium(IV), Plutonium(III/IV), and Cerium(III/IV) with DTPA
2012Co-Authors: Alex M. Brown, Alena Paulenova, Artem V. GelisAbstract:Aqueous complexation of Th(IV), U(IV), Np(IV), Pu(III/IV), and Ce(III/IV) with DTPA was studied by potentiometry, absorption spectrophotometry, and cyclic voltammetry at 1 M ionic strength and 25 °C. The stability constants for the 1:1 complex of each trivalent and tetravalent metal were calculated. From the potentiometric data, we report stability constant values for Ce(III)DTPA, Ce(III)HDTPA, and Th(IV)DTPA of log β101 = 20.01 ± 0.02, log β111 = 22.0 ± 0.2, and log β101 = 29.6 ± 1, respectively. From the absorption spectrophotometry data, we report stability constant values for U(IV)DTPA, Np(IV)DTPA, and Pu(IV)DTPA of log β101 = 31.8 ± 0.1, 32.3 ± 0.1, and 33.67 ± 0.02, respectively. From the cyclic voltammetry data, we report stability constant values for Ce(IV) and Pu(III) of log β101 = 34.04 ± 0.04 and 20.58 ± 0.04, respectively. The values obtained in this work are compared and discussed with respect to the ionic radius of each cationic metal
Alex M. Brown - One of the best experts on this subject based on the ideXlab platform.
-
aqueous complexation of thorium iv uranium iv neptunium iv plutonium iii iv and cerium iii iv with DTPA
Inorganic Chemistry, 2012Co-Authors: Alex M. Brown, Alena Paulenova, Artem V. GelisAbstract:Aqueous complexation of Th(IV), U(IV), Np(IV), Pu(III/IV), and Ce(III/IV) with DTPA was studied by potentiometry, absorption spectrophotometry, and cyclic voltammetry at 1 M ionic strength and 25 °C. The stability constants for the 1:1 complex of each trivalent and tetravalent metal were calculated. From the potentiometric data, we report stability constant values for Ce(III)DTPA, Ce(III)HDTPA, and Th(IV)DTPA of log β101 = 20.01 ± 0.02, log β111 = 22.0 ± 0.2, and log β101 = 29.6 ± 1, respectively. From the absorption spectrophotometry data, we report stability constant values for U(IV)DTPA, Np(IV)DTPA, and Pu(IV)DTPA of log β101 = 31.8 ± 0.1, 32.3 ± 0.1, and 33.67 ± 0.02, respectively. From the cyclic voltammetry data, we report stability constant values for Ce(IV) and Pu(III) of log β101 = 34.04 ± 0.04 and 20.58 ± 0.04, respectively. The values obtained in this work are compared and discussed with respect to the ionic radius of each cationic metal.
-
Aqueous Complexation of Thorium(IV), Uranium(IV), Neptunium(IV), Plutonium(III/IV), and Cerium(III/IV) with DTPA
2012Co-Authors: Alex M. Brown, Alena Paulenova, Artem V. GelisAbstract:Aqueous complexation of Th(IV), U(IV), Np(IV), Pu(III/IV), and Ce(III/IV) with DTPA was studied by potentiometry, absorption spectrophotometry, and cyclic voltammetry at 1 M ionic strength and 25 °C. The stability constants for the 1:1 complex of each trivalent and tetravalent metal were calculated. From the potentiometric data, we report stability constant values for Ce(III)DTPA, Ce(III)HDTPA, and Th(IV)DTPA of log β101 = 20.01 ± 0.02, log β111 = 22.0 ± 0.2, and log β101 = 29.6 ± 1, respectively. From the absorption spectrophotometry data, we report stability constant values for U(IV)DTPA, Np(IV)DTPA, and Pu(IV)DTPA of log β101 = 31.8 ± 0.1, 32.3 ± 0.1, and 33.67 ± 0.02, respectively. From the cyclic voltammetry data, we report stability constant values for Ce(IV) and Pu(III) of log β101 = 34.04 ± 0.04 and 20.58 ± 0.04, respectively. The values obtained in this work are compared and discussed with respect to the ionic radius of each cationic metal
Lode Schuerman - One of the best experts on this subject based on the ideXlab platform.
-
immunogenicity safety and reactogenicity of the 10 valent pneumococcal nontypeable haemophilus influenzae protein d conjugate vaccine and DTPA ipv hib when coadministered as a 3 dose primary vaccination schedule in the netherlands a randomized contro
Pediatric Infectious Disease Journal, 2011Co-Authors: Menno R Van Den Bergh, Lode Schuerman, Judith Spijkerman, Nancy Francois, Kristien Swinnen, Dorota Borys, Reinier H Veenhoven, Elisabeth A M SandersAbstract:Background Recent reviews have highlighted the unpredictability of immunologic interference when multivalent conjugated vaccines are coadministered with other pediatric vaccines. Objective To evaluate immunogenicity, safety, and reactogenicity of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV; Synflorix, GlaxoSmithKline Biologicals) and DTPA-IPV-Hib (Pediacel, Sanofi Pasteur MSD) when coadministered as a 3-dose primary vaccination course. Material and methods In a single-blind, single-center, randomized controlled trial in the Netherlands, healthy infants (n = 780) were randomly assigned (1:1:1) to receive either (1) PHiD-CV + DTPA-HBV-IPV/Hib (Infanrix Hexa, GlaxoSmithKline Biologicals), (2) PHiD-CV + DTPA-IPV-Hib, or (3) 7-valent pneumococcal conjugate vaccine (Prevenar/Prevnar, Pfizer Inc.) + DTPA-IPV-Hib at 2, 3, and 4 months of age. Blood samples were collected 1 month after dose 3. Diary cards were used to record safety and reactogenicity. Results Antibody concentrations elicited by PHiD-CV coadministered with DTPA-IPV-Hib were noninferior to those following DTPA-HBV-IPV/Hib coadministration for 9 of 10 vaccines pneumococcal serotypes and protein D. For serotype 18C (conjugated to tetanus toxoid), the antibody concentration was higher with DTPA-HBV-IPV/Hib coadministration (1.73 vs. 1.07 μg/mL). The percentages of infants with antibody concentrations ≥0.2 μg/mL (68.9%-100% in the PHiD-CV + DTPA-HBV-IPV/Hib group vs. 64.9%-100% in the PHiD-CV + DTPA-IPV-Hib group) and with measurable opsonophagocytic activity (56.1%-100% in the PHiD-CV + DTPA-HBV-IPV/Hib group vs. 61.1%-100% in the PHiD-CV + DTPA-IPV-Hib group) were comparable for all serotypes in both PHiD-CV groups. Group differences in antibody responses to the DTPA-IPV-Hib antigens remained within the predefined limit for noninferiority. Safety and reactogenicity profiles were comparable across groups. Conclusions : PHiD-CV and DTPA-IPV-Hib were immunogenic and well tolerated when coadministered as a 3-dose primary vaccination course.
-
a comparison of booster immunisation with a combination DTPA ipv vaccine or DTPA plus ipv in separate injections when co administered with mmr at age 4 6 years
Vaccine, 2006Co-Authors: Helen Marshall, Terry Nolan, Don Roberton, Peter Richmond, Stephen B Lambert, Jeannemarie Jacquet, Lode SchuermanAbstract:This study evaluated GSK's combined DTPA-IPV vaccine (Infanrix™-IPV) given as a fifth consecutive acellular pertussis booster dose in conjunction with the second dose of MMR vaccine (Priorix™) in children aged 4–6 years. The immunogenicity and reactogenicity of this vaccine regimen was compared with separate injections of DTPA and IPV when given concomitantly with MMR. A cohort of 362 children previously primed with four doses of DTPA and OPV, and a single dose of MMR were randomized to receive either DTPA-IPV + MMR (N = 181) or DTPA + IPV + MMR (N = 181). Antibody concentrations were measured prior to and 1 month after the booster dose. After immunisation all subjects from both groups had seroprotective antibody levels against diphtheria, tetanus and the three poliovirus serotypes, ≥96% showed vaccine response to PT, FHA and PRN, all were seropositive to mumps and rubella, and all but one subject were seropositive to measles. Immunogenicity results for each component antigen were similar for DTPA-IPV and separately co-administered DTPA and IPV. Local reactions were common with 24.0% and 31.1% of children experiencing swelling >50 mm at the DTPA-IPV and DTPA injection sites, respectively. The DTPA-IPV combination did not increase the incidence or intensity of adverse events compared with separately administered DTPA + IPV. The response to the concomitantly administered MMR vaccine was similar in the two groups and similar to previously reported responses for a second dose of MMR. This combined DTPA-IPV vaccine has a similar reactogenicity profile to DTPA, is immunogenic when given as a booster dose at 4–6 years of age, and has no impact on the immunogenicity of a co-administered second dose of MMR vaccine.
-
combined reduced antigen content diphtheria tetanus acellular pertussis and polio vaccine DTPA ipv for booster vaccination of adults
Vaccine, 2005Co-Authors: E Grimprel, Frank Von Sonnenburg, Roland Sanger, Veronique Abitbol, Joanne Wolter, Lode SchuermanAbstract:Many countries recommend diphtheria, tetanus and/or poliomyelitis boosters in adolescents or adults and the need for pertussis booster vaccination beyond childhood is increasingly recognized. A new combined reduced-antigen-content DTPA-IPV vaccine provides booster vaccination against all four diseases in one single injection. The immunogenicity and safety of the DTPA-IPV vaccine was compared to that of licensed DTPA + IPV or Td-IPV vaccines in 806 adolescents >14 years of age and adults with a heterogeneous vaccination history. The DTPA-IPV vaccine was immunogenic and well tolerated. No clinically significant differences were observed between groups. Anti-tetanus antibody kinetics indicated that each of the vaccines could be used for tetanus prophylaxis in acute wound management. For all vaccines, the lowest post-vaccination antibody concentrations were observed in subjects >40 years of age, those seronegative prior to vaccination and those subjects whose last vaccination was ≥20 years ago. In conclusion, DTPA-IPV vaccination of subjects over 14 years of age was as immunogenic and well tolerated as the licensed DTPA + IPV or Td-IPV vaccines. Vaccination coverage of adults is poor and the use of combined vaccines such as DTPA-IPV during vaccination visits, or for wound management, maximizes opportunities for boosting in these difficult to reach age groups.
Su-geun Yang - One of the best experts on this subject based on the ideXlab platform.
-
enhanced conjugation stability and blood circulation time of macromolecular gadolinium DTPA contrast agent
Materials Science and Engineering: C, 2016Co-Authors: Ratchapol Jenjob, Jung Yeon Ghee, Zheyu Shen, Xiaoxia Wu, Su-geun YangAbstract:Abstract In this study, we prepared macromolecular MR T1 contrast agent: pullulan-conjugated Gd diethylene triamine pentaacetate (Gd-DTPA-Pullulan) and estimated residual free Gd 3 + , chelation stability in competition with metal ions, plasma and tissue pharmacokinetics, and abdominal MR contrast on rats. Residual free Gd 3 + in Gd-DTPA-Pullulan was measured using colorimetric spectroscopy. The transmetalation of Gd 3 + incubated with Ca 2 + was performed by using a dialysis membrane (MWCO 100–500 Da) and investigated by ICP-OES. The plasma concentration profiles of Gd-DTPA-Pullulan were estimated after intravenous injection at a dose 0.1 mmol/kg of Gd. The coronal-plane abdominal images of normal rats were observed by MR imaging. The content of free Gd 3 + , the toxic residual form, was less than 0.01%. Chelation stability of Gd-DTPA-Pullulan was estimated, and only 0.2% and 0.00045% of Gd 3 + were released from Gd-DTPA-Pullulan after 2 h incubation with Ca 2 + and Fe 2 + , respectively. Gd-DTPA-Pullulan displayed the extended plasma half-life (t 1/2,α = 0.43 h, t 1/2,β = 2.32 h), much longer than 0.11 h and 0.79 h of Gd-EOB-DTPA. Abdominal MR imaging showed Gd-DTPA-Pullulan maintained initial MR contrast for 30 min. The extended plasma half-life of Gd-DTPA-Pullulan probably allows the prolonged MR acquisition time in clinic with enhanced MR contrast.
-
The performance of gadolinium diethylene triamine pentaacetate-pullulan hepatocyte-specific T1 contrast agent for MRI.
Biomaterials, 2011Co-Authors: Su-geun Yang, Yong Sun Jeon, In Suh Park, Kun NaAbstract:Abstract The magnetic resonance (MR) functionalities of pullulan-conjugated gadolinium diethylene triamine pentaacetate (Gd-DTPA-Pullulan) as a new hepatocyte-specific contrast agent were evaluated. Pullulan, which specifically accumulates on hepatocytes via asialoglycoprotein receptors, was chemically linked with Gd-DTPA. Gd-DTPA-Pullulan displayed three times greater contrast enhancement than Gd-DTPA-BMA (Omniscan ® ) in delayed MR imaging (MRI) on orthotopic rat hepatocarcinoma (HCC). This contrast effect lasted up to 24 h. In particular, Gd-DTPA-Pullulan displayed a discriminative MR contrast on the regenerative and malignant hepatic nodules sequentially observed during the progress of cirrhotic HCC. Approximately 50% of injected Gd-DTPA-Pullulan was eliminated via the hepato-biliary system. IC 50 of Gd-DTPA-Pullulan on Chang liver cells was much higher than Gd-DTPA and Gd-DTPA-BMA (309.1 ± 11.2, 173.5 ± 15.5 and 49.4 ± 8.9 μM, respectively). Any significant toxicities of Gd-DTPA-Pullulan at the conventional dose on the rats weren’t detected on histology studies. Gd-DTPA-Pullulan worked as a hepatocyte-specific MR contrast agent with increased MR functionalities and an acceptable safety profile setting the scene for future clinical trials.
Philipp Wiggermann - One of the best experts on this subject based on the ideXlab platform.
-
volume assisted estimation of liver function based on gd eob DTPA enhanced mr relaxometry
European Radiology, 2016Co-Authors: M Haimerl, Mona Schlabeck, N Verloh, Florian Zeman, Claudia Fellner, Dominik Nickel, Ana Paula Barreiros, Martin Loss, Christian Stroszczynski, Philipp WiggermannAbstract:To determine whether liver function as determined by indocyanine green (ICG) clearance can be estimated quantitatively from hepatic magnetic resonance (MR) relaxometry with gadoxetic acid (Gd-EOB-DTPA). One hundred and seven patients underwent an ICG clearance test and Gd-EOB-DTPA–enhanced MRI, including MR relaxometry at 3 Tesla. A transverse 3D VIBE sequence with an inline T1 calculation was acquired prior to and 20 minutes post-Gd-EOB-DTPA administration. The reduction rate of T1 relaxation time (rrT1) between pre- and post-contrast images and the liver volume-assisted index of T1 reduction rate (LVrrT1) were evaluated. The plasma disappearance rate of ICG (ICG-PDR) was correlated with the liver volume (LV), rrT1 and LVrrT1, providing an MRI-based estimated ICG-PDR value (ICG-PDRest). Simple linear regression model showed a significant correlation of ICG-PDR with LV (r = 0.32; p = 0.001), T1post (r = 0.65; p < 0.001) and rrT1 (r = 0.86; p < 0.001). Assessment of LV and consecutive evaluation of multiple linear regression model revealed a stronger correlation of ICG-PDR with LVrrT1 (r = 0.92; p < 0.001), allowing for the calculation of ICG-PDRest. Liver function as determined using ICG-PDR can be estimated quantitatively from Gd-EOB-DTPA–enhanced MR relaxometry. Volume-assisted MR relaxometry has a stronger correlation with liver function than does MR relaxometry. • Measurement of T1 relaxation times in Gd-EOB-DTPA–enhanced MR imaging quantifies liver function. • Volume-assisted Gd-EOB-DTPA–enhanced MR relaxometry has stronger correlation with ICG-PDR than does Gd-EOB-DTPA–enhanced MR relaxometry. • Gd-EOB-DTPA–enhanced MR relaxometry may provide robust parameters for detecting and characterizing liver disease. • Gd-EOB-DTPA–enhanced MR relaxometry may be useful for monitoring liver disease progression. • Gd-EOB-DTPA–enhanced MR relaxometry has the potential to become a novel liver function index.
